Company Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.
Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.
The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
The company serves to hemodialysis clinics. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012.
Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
| Country | United States |
| Founded | 1994 |
| IPO Date | Jan 27, 1998 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 237 |
| CEO | Mark Strobeck |
Contact Details
Address: 30142 South Wixom road Wixom, Michigan 48393 United States | |
| Phone | 248 960 9009 |
| Website | rockwellmed.com |
Stock Details
| Ticker Symbol | RMTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001041024 |
| CUSIP Number | 774374300 |
| ISIN Number | US7743743004 |
| Employer ID | 38-3317208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Strobeck Ph.D. | President, Chief Executive Officer and Director |
| Jesse Neri | Senior Vice President of Finance |
| Megan C. Timmins | Executive Vice President, Chief Legal Officer and Secretary |
| Timothy T. Chole | Senior Vice President and Chief Commercial Officer |
| Heather R. Hunter | Senior Vice President and Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2024 | EFFECT | Notice of Effectiveness |
| Oct 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 3, 2024 | SCHEDULE 13G/A | Filing |
| Oct 1, 2024 | 144 | Filing |
| Oct 1, 2024 | 144 | Filing |
| Aug 20, 2024 | SCHEDULE 13G/A | Filing |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |